Io Biotech, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
IOBT
Io Biotech, INCIO Biotech reports substantial doubt about its ability to continue as a going concern, following the FDA's recommendation against a BLA submission for its lead cancer vaccine, Cylembio, despite promising Phase 3 PFS data.
IOBT
Io Biotech, INCIO Biotech reports increased losses and a going concern warning, as its lead cancer vaccine Cylembio narrowly missed statistical significance in a pivotal Phase 3 melanoma trial.
IOBT
Io Biotech, INCIO Biotech, a clinical-stage biopharmaceutical company, announces its Q1 2025 financial results and provides an update on the progress of its Phase 3 trial for Cylembio in advanced melanoma.
IOBT
Io Biotech, INCIO Biotech's Q3 2024 report details financial results and provides updates on its clinical programs, including the Phase 3 trial for IO102-IO103.
IOBT
Io Biotech, INCIO Biotech, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results and provided an update on its clinical development programs, including its Phase 3 trial for IO102-IO103.
IOBT
Io Biotech, INCIO Biotech's first quarter 2024 results show a net loss of $19.5 million, with ongoing clinical trial progress for their cancer vaccine candidates.